Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07119957
Recruiting Not applicable

ProspEXPO : Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome

NCT07119957 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Angers
Phase
Not applicable
Started
2025-12-17
Last updated
2026-06-10

Condition(s) studied

Cirrhoses, LiverCarcinoma Liver

Investigational drug(s) / intervention(s)

Blood, urine and stool biocollection

Blood, urine and stool biocollection: Collection of blood, urine and stool sampling in order to build up a biocollection

Study summary

The aim of the study is to build up a bio-collection of biological samples from patients with cirrhosis. Further work using this bio-collection will permit to describe the influence of different exposome factors (nutrition, physical activity, socio-demographic conditions, tobacco, alcohol, pollutants) on the occurrence of the main type of liver cancer (called HCC).

Indeed, in the vast majority of cases, HCC develops within cirrhosis, and the factors that precipitate the progression of cirrhotic patients to HCC remain largely unknown.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Presence of metabolic and/or alcoholic steatotic liver disease, as defined by the new nomenclature (MASLD, ALD, or mixed MetALD) * Liver biopsy performed (less than 2 months ago) or planned as part of treatment for diagnosis of cirrhosis ("Control" group without HCC) or diagnosis of HCC on cirrhosis ("Case" group) * Patient affiliated to or benefiting from a social security scheme * Patient having signed an informed consent to participate in the study (bio-collection) Exclusion Criteria: * Causes of chronic liver disease other than MASLD, ALD, or MetALD * Decompensation of cirrhosis in the two years prior to inclusion (ascites, hepatic encephalopathy, gastrointestinal variceal hemorrhage, liver failure, hepatorenal syndrome) * For the "Control" group: history of hepatocellular carcinoma * Pregnant, breast-feeding or parturient women * Persons deprived of liberty by judicial or administrative decision

Primary outcome measure(s)

  • Blood sample for biocollection — Baseline
    Blood samples will be collected in order to create a biocollection. Biological parameters will be defined only with future studies (no biological parameter scheduled for this study).
  • Urinary sample for biocollection — Baseline
    Urinary samples will be collected in order to create a biocollection. Biological parameters will be defined only with future studies (no biological parameter scheduled for this study).
  • faecal sample for biocollection — Baseline
    Faecal samples will be collected in order to create a biocollection. Biological parameters will be defined only with future studies (no biological parameter scheduled for this study).

Trial sites (4)

FacilityCityRegionStatus
Angers University Hospital Angers France Recruiting
Centre Eugène Marquis (Oncology center) Rennes France Not Yet Recruiting
Rennes University Hospital, Hepatogastroenteroly Department Rennes France Not Yet Recruiting
Tours University Hospital, HepatoGastroenterology Department Tours France Not Yet Recruiting

More University Hospital, Angers trials in France

PETRA: Pictorial Assessment of Task Occurrence and Upper Limb Avoidance Behaviors Recruiting
Medical Honey for Wound Treatment in Intensive Care. (MICARéa) Randomized, Controlled, Single-center Pilot Study. Recruiting
Strategies for Weaning From External Ventricular Drainage Starting soon
Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1 Active, not recruiting
Disparities in Myocardial Infarction Remodeling According to Gender Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07119957 on ClinicalTrials.gov ↗ ← All trials in France